Non-Current Assets
Indefinite-Lived Intangible Assets
Pfizer Indefinite-Lived Intangible Assets decreased by 2.6% to $21.64B in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryMarket Position
SignalHigher is better
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
Stability or growth indicates the sustained value of the company's brand or core intellectual property.
Detailed definition
These are intangible assets, such as brand names or certain licenses, that are expected to provide value for an unlimite...
Peer comparison
Standard for companies with strong brand equity or long-term regulatory licenses.
Metric ID:
indefinite_lived_intangible_assetsHistorical Data
5 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $22.22B | $21.64B |
| QoQ Change | — | — | — | — | -2.6% |
Range$0.00 – $22.22B
Indefinite-Lived Intangible Assets at Other Companies
Frequently Asked Questions
- What is Pfizer's indefinite-lived intangible assets?
- Pfizer (PFE) reported indefinite-lived intangible assets of $21.64B in Q1 2026.
- What does indefinite-lived intangible assets mean?
- Intangible assets like brands that are expected to last forever and are not depreciated.